Stephan Schilling

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2506396/publications.pdf

Version: 2024-02-01

34	2,052	430874 18	477307 29
papers	citations	h-index	g-index

34	34	34	1834
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-Î². Nature, 2012, 485, 651-655.	27.8	369
2	Glutaminyl cyclase inhibition attenuates pyroglutamate AÎ² and Alzheimer's diseaseâ€“like pathology. Nature Medicine, 2008, 14, 1106-1111.	30.7	316
3	On the Seeding and Oligomerization of pGlu-Amyloid Peptides (in vitro). Biochemistry, 2006, 45, 12393-12399.	2.5	238
4	Pyroglutamate Formation Influences Solubility and Amyloidogenicity of Amyloid Peptides. Biochemistry, 2009, 48, 7072-7078.	2.5	171
5	Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Letters, 2004, 563, 191-196.	2.8	155
6	Pyroglutamate-3 Amyloid-Î² Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Diseaseâ€“Like Transgenic Mouse Models. American Journal of Pathology, 2013, 183, 369-381.	3.8	102
7	Glutaminyl Cyclase in Human Cortex: Correlation with (pGlu)-Amyloid-Î² Load and Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 39, 385-400.	2.6	90
8	Nâ€terminal pyroglutamate formation of AÎ²38 and AÎ²40 enforces oligomer formation and potency to disrupt hippocampal longâ€term potentiation. Journal of Neurochemistry, 2012, 121, 774-784.	3.9	76
9	Passive Immunization against Pyroglutamate-3 Amyloid-Î² Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study. Neurodegenerative Diseases, 2012, 10, 265-270.	1.4	63
10	Substrate Specificity of Glutaminyl Cyclases from Plants and Animals. Biological Chemistry, 2003, 384, 1583-92.	2.5	59
11	Heterologous Expression and Characterization of Human Glutaminyl Cyclase:Â Evidence for a Disulfide Bond with Importance for Catalytic Activity. Biochemistry, 2002, 41, 10849-10857.	2.5	58
12	Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimerâ€™s Diseaseâ€”Studies on Relation to Effective Target Occupancy. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 119-130.	2.5	50
13	An anti-pyroglutamate-3 AÎ² vaccine reduces plaques and improves cognition in APPswe/PS1Î”E9 mice. Neurobiology of Aging, 2015, 36, 3187-3199.	3.1	45
14	Passive AÎ² Immunotherapy: Current Achievements and Future Perspectives. Molecules, 2018, 23, 1068.	3.8	41
15	Glutaminyl Cyclases Display Significant Catalytic Proficiency for Glutamyl Substrates. Biochemistry, 2009, 48, 11831-11833.	2.5	38
16	IsoQC (QPCTL) knock-out mice suggest differential substrate conversion by glutaminyl cyclase isoenzymes. Biological Chemistry, 2016, 397, 45-55.	2.5	23
17	Isolation and Characterization of Glutaminyl Cyclases from Drosophila:â€‰ Evidence for Enzyme Forms with Different Subcellular Localization. Biochemistry, 2007, 46, 10921-10930.	2.5	22
18	Focused ultrasound with anti-pGlu3 AÎ² enhances efficacy in Alzheimer's disease-like mice via recruitment of peripheral immune cells. Journal of Controlled Release, 2021, 336, 443-456.	9.9	21

#	Article	IF	Citations
19	First insight into structure-activity relationships of selective meprin Î² inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2428-2431.	2.2	20
20	Development of the clinical candidate PBD-C06, a humanized pGlu3-AÎ²-specific antibody against Alzheimerâ€™s disease with reduced complement activation. Scientific Reports, 2020, 10, 3294.	3.3	17
21	Phosphate ions and glutaminyl cyclases catalyze the cyclization of glutaminyl residues by facilitating synchronized proton transfers. Bioorganic Chemistry, 2015, 60, 98-101.	4.1	13
22	A glutaminyl cyclase-catalyzed Î±-synuclein modification identified in human synucleinopathies. Acta Neuropathologica, 2021, 142, 399-421.	7.7	13
23	Natural Products from Plants and Algae for Treatment of Alzheimerâ€™s Disease: A Review. Biomolecules, 2022, 12, 694.	4.0	12
24	Hydrazides Are Potent Transition-State Analogues for Glutaminyl Cyclase Implicated in the Pathogenesis of Alzheimerâ€™s Disease. Biochemistry, 2020, 59, 2585-2591.	2.5	11
25	Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain AÎ² Pathology in Transgenic Mice. International Journal of Molecular Sciences, 2021, 22, 11791.	4.1	10
26	Continuous assays for meprin alpha and beta using prolyl tripeptidyl aminopeptidase (PtP) from Porphyromonas gingivalis. Analytical Biochemistry, 2018, 559, 11-16.	2.4	7
27	Structure and Dynamics of Meprin Î² in Complex with a Hydroxamate-Based Inhibitor. International Journal of Molecular Sciences, 2021, 22, 5651.	4.1	7
28	Continuous assays of glutaminyl cyclase: from development to application. Spectroscopy, 2004, 18, 363-373.	0.8	4
29	Evidence for Enhanced Efficacy of Passive Immunotherapy against Beta-Amyloid in CD33-Negative 5xFAD Mice. Biomolecules, 2022, 12, 399.	4.0	1
30	P1-077: EVIDENCE FOR INVOLVEMENT OF MEPRIN B IN FORMATION OF N-TRUNCATED AND PYROGLUTAMATE -MODIFIED (PGLU) ABETA. , 2014, 10, P331-P331.		0
31	P4â€298: Meprin Î² is Associated with Formation of Pyroglutamateâ€Modified AÎ² Peptides. Alzheimer's and Dementia, 2016, 12, P1147.	0.8	0
32	[P4â€“457]: Nâ€TRUNCATED AND PYROGLUTAMATEâ€MODIFIED AÎ² ACCELERATES AGGREGATION OF Î±â€SYNUCLEIN IN VITRO. Alzheimer's and Dementia, 2017, 13, P1505.	0.8	0
33	P1â€099: COMBINATION OF A GLUTAMINYL CYCLASE INHIBITOR (PQ912) AND A PYROGLUTAMATEâ€AÎ² SPECIFIC ANTIBODY (PBDâ€M06) SHOWS ADDITIVE EFFECTS IN A MOUSE MODEL WITH ALZHEIMER'S DISEASEâ€LIKE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P309.	0.8	0
34	P2â€056: TARGETING ISOASPARTATEâ€MODIFIED AÎ²: A DIFFERENTIAL APPROACH OF PASSIVE IMMUNOTHERAPY. Alzheimer's and Dementia, 2018, 14, P687.	0.8	0